Preparing Biopharma for 2026 and Beyond

As biopharmaceutical companies roll full steam into 2026, the industry finds itself balancing innovation with pragmatism. Economic uncertainty, evolving workforce dynamics, and scientific complexity are reshaping how biotherapies are discovered, developed, and manufactured. The articles in this issue reflect a recalibrating industry that is leaning on technology, data, and strategic foresight to remain resilient.

Our cover story, “How Biopharma Navigates the 2026 Economic Shift,” explores how AI and automation are moving from aspirational tools to operational necessities. These technologies are increasingly central to closing talent gaps, stabilizing costs, and accelerating development and manufacturing in a more constrained economic environment.

Workforce sentiment is examined in our special report, “Bio/pharma Manufacturing Professionals Are Staying Put Despite Growing Uncertainty.” While optimism has softened, survey data show professionals remain intellectually engaged and committed, an important signal for an industry that depends on deep expertise and continuity.

Innovation in development continues to push boundaries. “Next-Generation Modalities Drive New Antibody Discovery” highlights how multifunctional antibody platforms are emerging, shaped by the dual pressures of manufacturing scalability and regulatory acceleration. These advances connect directly to manufacturing strategy, particularly in advanced therapies. In “What Are the Benefits of Single-Use in CGT Manufacturing?” we examine how single-use systems are enabling flexibility, efficiency, and risk reduction in cell and gene therapy production.

Analytics and automation also play a growing role earlier in discovery. “High-Throughput Systems Refine Protein Engineering”shows how data-driven platforms are shortening development timelines while improving control and reproducibility.

In “Ask the Expert,” Susan J. Schniepp and Jane Zhang discuss how evolving packaging trends and supply chain controls underscore a renewed focus on protection, reliability, and preparedness, reminding us that resilience is built as much through operational discipline as through innovation.

Together, these stories reflect a biopharma industry adapting with intention, focused on smarter systems, sustainable growth, and long-term stability.